Wednesday, Compugen Ltd. (CGEN) reported positive results from a recently completed in vivo study of its novel peptide antagonist, CGEN-25007, a possible treatment for inflammatory diseases and other immune related diseases. CGEN-25007, a novel peptide antagonist of the gp96 protein, was predicted using Compugen's DAC Blockers discovery platform
CGEN-25007 was initially predicted using the company's DAC blockers platform, designed to predict peptides that block proteins of interest from achieving certain disease-associated conformations. The company found that CGEN-25007 binds recombinant gp96 in a dose dependent manner.
The data from the vivo study showed CGEN-25007 to have immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.
Using an animal model of endotoxemia, CGEN-25007 was shown to exhibit a profound and dose-dependent anti-inflammatory activity.
In this study, the novel peptide was administered following the introduction of lipopolysaccharide, a bacterial substance that induces a strong response in the animal immune system leading to systemic inflammation.
The company said that the administration of CGEN-25007 resulted in a decrease of about 50% in the serum levels of inflammatory cytokines and chemokines, including tumor necrosis factor alpha, IL-6, interferon-gamma, MIP-1a and MIP-2.
Compugen indicated that CGEN-25007 was also found to strongly inhibit the secretion of inflammatory cytokines from human peripheral blood mononuclear cells.
CGEN is currently trading at $2.24, up 12 cents or 5.66%.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.